{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:06Z","timestamp":1787027046595,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013831","name":"Universitatea de Medicin\u0103 \u015fi Farmacie din Craiova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Adherence to direct-acting antivirals (DAAs) could be a predictor of chronic viral hepatitis C (HCV) therapeutic failure. We examined the perceptions of patients receiving DAAs to determine how cognitive factors influence their decision to maintain adherence. Also, we explored the threshold of DAAs adherence for obtaining sustained virologic response (SVR) among patients with HCV, in order to better implement a strategy that improves the DAAs adherence in the future clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-arm prospective study was performed. Patients with HCV that started and completed DAAs treatment in the County Hospital of Craiova, Dolj, Romania, were enrolled. Patients\u2019 medication adherence was assessed using the HCV-AD10 questionnaire, and the cognitive emotion regulation was measured with CERQ questionnaire (five positive\/adaptive cognitive emotion-regulation domains and four negative\/maladaptive domains). Spearman correlation analysis was conducted to explore the relationships between adherence and different factors. ROC-curves were used to evaluate the adherence threshold to achieve SVR. A linear regression model was performed to analyze the primary outcome (DAAs adherence) to be the target variable based on given independent variables (age, treatment duration, severity of HCV, the nine adaptive and maladaptive strategies).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      368 patients (mean age: 61\u00a0years) with HCV diagnosed 4.05 \u00b1 6.38 (average) years ago were enrolled. Mean (\u00b1SD) adherence via HCV-AD10 was 91.51 \u00b1 8.34, and the proportion of the participants achieving SVR was 96%. Patients with an adherence less than 84% (5 patients, 1.36%) was considered nonadherent and they have a high probability of not achieving response (sensitivity and specificity of 83% and 80%, respectively). We obtained significantly higher values of three adaptive strategies between adherent and nonadherent patients following DAAs treatment: in positive refocusing (\n                      <jats:italic>p<\/jats:italic>\n                      -value = 0.044), refocus on planning (\n                      <jats:italic>p<\/jats:italic>\n                      -value = 0.037), and positive reappraisal (\n                      <jats:italic>p<\/jats:italic>\n                      -value = 0.047).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The interplay between the three adaptive strategies of the cognitive emotion regulation and the enhancement of DAAs adherence contributes to a more holistic comprehension of patient behavior in the context of HCV treatment. Increasing refocusing and planning using goal setting and assisting patients in establishing specific, achievable goals can be crucial strategies for clinicians aiming to improve adherence among their patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1369166","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:51:34Z","timestamp":1730778694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C"],"prefix":"10.3389","volume":"15","author":[{"given":"Adina","family":"Turcu-Stiolica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Paula","family":"Doica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan Silviu","family":"Ungureanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Simona","family":"Subtirelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Nicolae","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan-Aurelian","family":"Turcu-Stiolica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Rogoveanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Ionut","family":"Gheonea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jval.2023.10.016","article-title":"Systematic review of outcomes for assessment of medication adherence enhancing interventions: an ISPOR special interest group report","author":"Agh","year":"2023","journal-title":"Value Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"21501327211008051","DOI":"10.1177\/21501327211008051","article-title":"Barriers to completing therapy for hepatitis C with direct-acting antivirals: a real-life experience from a single treatment center in Egypt","volume":"12","author":"Ahmed","year":"2021","journal-title":"J. Prim. Care. Community. Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann. Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"ciad319","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijantimicag.2018.12.010","article-title":"Hepatitis C virus therapy: No one will be left behind","volume":"53","author":"Bourli\u00e8re","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrd.2017.1","article-title":"Poor medication adherence in clinical trials: consequences and solutions","volume":"16","author":"Breckenridge","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2893.2010.01343.x","article-title":"Patient preferences and assessment of likely adherence to hepatitis C virus treatment","volume":"18","author":"Brett Hauber","year":"2011","journal-title":"J. Viral. Hepat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14423\/SMJ.0000000000000750","article-title":"Measuring adherence to hepatitis C direct-acting antiviral medications: using the VAS in an HCV treatment clinic","volume":"111","author":"Burton","year":"2018","journal-title":"South. Med. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s11096-019-00917-0","article-title":"Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment","volume":"41","author":"Campos Fern\u00e1ndez de Sevilla","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e16242","DOI":"10.1097\/MD.0000000000016242","article-title":"HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics","volume":"98","author":"Chehl","year":"2019","journal-title":"Medicine"},{"key":"B9","volume-title":"Prevalence of Viral Hepatitis B and Viral Hepatitis C Infection among Health Care Providers from Adult and Children Health Care and Social Assistance Centers; Centrul Medical de Diagnostic si Tratament","author":"Constantin","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0399-8320(08)73994-0","article-title":"Transient elastography (FibroScan)","volume":"32","author":"de L\u00e9dinghen","year":"2008","journal-title":"Gastroenterol. Clin. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/v14061325","article-title":"Direct-acting antiviral agents for hepatitis C virus infection-from drug discovery to successful implementation in clinical practice","volume":"14","author":"Dietz","year":"2022","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.3390\/ijerph18073694","article-title":"Telemedicine chronic viral hepatitis C treatment during the lockdown period in Romania: a pilot study","volume":"18","author":"Doica","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.12865\/CHSJ.49.03.02","article-title":"Association between direct-acting agents adherence and health-related quality of life of patients with hepatitis C","volume":"49","author":"Doica","year":"2023","journal-title":"Curr. Health Sci. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/jvh.13454","article-title":"High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting","volume":"28","author":"Fabbiani","year":"2021","journal-title":"J. Viral. Hepat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/s0191-8869(00)00113-6","article-title":"Negative life events, cognitive emotion regulation and emotional problems","volume":"30","author":"Garnefski","year":"2021","journal-title":"Individ. Differ."},{"key":"B16","article-title":"CERQ manual de utilizare a chestionarului de coping cognitiv-emo\u021bional, (adaptarea \u0219i standardizarea CERQ pe popula\u021bia din Rom\u00e2nia Adela Per\u021be-coordonator)","author":"Garnefski","year":"2010","journal-title":"ASCR Clujn"},{"key":"B17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.46743\/2160-3715\/2018.2740","article-title":"Patient perspectives on adherence to the new hepatitis C antiviral medications: \u201cA new lease on life\u201d","volume":"23","author":"Giordano","year":"2018","journal-title":"Qual. Rep."},{"key":"B18","unstructured":"Summary of harvoni characteristics2014"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/cid\/ciab334","article-title":"Hepatitis C virus direct-acting antiviral treatment adherence patterns and sustained viral response among people who inject drugs treated in opioid agonist therapy programs","volume":"73","author":"Heo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/healthcare9060651","article-title":"Hepatitis C virus prevalence and risk factors in a village in northeastern Romania-A population-based screening-the first step to viral micro-elimination","volume":"9","author":"Huiban","year":"2021","journal-title":"Healthc. (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","article-title":"Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research","volume":"13","author":"Kvarnstr\u00f6m","year":"2021","journal-title":"Pharmaceutics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1093412","DOI":"10.3389\/fpsyg.2023.1093412","article-title":"Effects of positive reappraisal and self-distancing on the meaningfulness of everyday negative events","volume":"14","author":"Lau","year":"2023","journal-title":"Front. Psychol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"104288","DOI":"10.1016\/j.drugpo.2023.104288","article-title":"Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: the HERO study","volume":"15","author":"Lopes","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/medicina57090986","article-title":"Direct-acting antiviral use for genotype 1b hepatitis C patients with associated hematological disorders from Romania","volume":"57","author":"Marincu","year":"2021","journal-title":"Medicina"},{"key":"B24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1586\/14737159.7.5.481","article-title":"FibroMAX: towards a new universal biomarker of liver disease?","volume":"7","author":"Morra","year":"2007","journal-title":"Expert Rev. Mol. Diagn"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0193945914524639","article-title":"Stressors may compromise medication adherence among adults with diabetes and low socioeconomic status","volume":"36","author":"Osborn","year":"2014","journal-title":"West J. Nurs. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s10620-019-05590-x","article-title":"Determinants of hepatitis C treatment adherence and treatment completion among veterans in the direct acting antiviral era","volume":"64","author":"Patel","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2018.08.006","article-title":"Methods for measuring multiple medication adherence: a systematic review-report of the ispor medication adherence and persistence special interest group","volume":"22","author":"Pednekar","year":"2019","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","article-title":"High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study","volume":"10","author":"Petersen","year":"2016","journal-title":"Hepatol. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.vhri.2016.07.006","article-title":"The development of the Romanian scorecard HTA system","volume":"10","author":"Radu","year":"2016","journal-title":"Value Health Reg. issues."},{"key":"B31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/liv.12467","article-title":"Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles","volume":"34","author":"Searson","year":"2014","journal-title":"Liver Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18176\/resp.00033","article-title":"Patients\u2019 preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection","volume":"23","author":"Simon","year":"2021","journal-title":"Rev. Esp. Sanid. Penit."},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.japh.2018.10.020","article-title":"Hepatitis C virus direct-acting antiviral non-adherence: relationship to sustained virologic response and identification of at-risk patients","volume":"59","author":"Slevin","year":"2019","journal-title":"J. Am. Pharm. Assoc."},{"key":"B39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/08870446.2015.1012195","article-title":"The Hepatitis C treatment experience: patients\u2019 perceptions of the facilitators of and barriers to uptake, adherence and completion","volume":"30","author":"Sublette","year":"2015","journal-title":"Psychol. and Health"},{"key":"B35","unstructured":"Order of national health insurance2020"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/pharmaceutics13101683","article-title":"Development and validation of a questionnaire to measure medication adherence to direct-acting agents in patients with hepatitis C","volume":"13","author":"Turcu-Stiolica","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:51:38Z","timestamp":1730778698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":41,"alternative-id":["10.3389\/fphar.2024.1369166"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1369166","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"article-number":"1369166"}}